Epithalon
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Epithalon is listed as anti-aging / telomere.
- •Telomere elongation
- •Anti-aging
- •Circadian regulation
- •Oncostatic (research)
Regulatory status: Not FDA-approved; research use.
Structure & Properties
Compound: Epithalon; also known as Epitalon, Epithalamin.
Pharmacologic class: Anti-aging / Telomere.
Known delivery routes: Subcutaneous, Intravenous.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Tetrapeptide — activates telomerase enzyme; regulates melatonin secretion via pineal gland; antioxidant; normalizes cortisol/sex hormone decline with aging.
- •Reported telomerase activation in vitro
- •Sleep and circadian improvement
- •Anti-aging biomarker support (preliminary)
Human Research
Evidence grade: Pre-clinical / Observational
Evidence is primarily preclinical or observational; human effectiveness and long-term safety are not established.
Laboratory Research
Russian animal and limited human observational data (Khavinson)
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
Once daily SubQ, evening. Typical short courses of 10–20 days, 1–2× per year.
Potential interactions and combinations to avoid
- •Active malignancy (theoretical)
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Limited human RCT data
- •Long-term safety unproven
- •Sourcing concerns
Contraindications
- •Active malignancy (theoretical)
- •Pregnancy
- •Any current or prior cancer diagnosis (apoptotic and telomerase pathways are tumor-relevant)
- •Impaired hepatic or renal clearance (senescent-cell debris burden)
- •Active wound healing or post-surgical recovery (senescent cells participate in repair)
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 5–10 mg/day (10–20-day cycles)
Frequency: Daily within short cycles
Cycling: 10–20 days daily, 2–4 cycles per year.
Subcutaneous (SubQ)
Default route for most research and therapeutic peptides — best absorption for reconstituted powder.
31G × 5/16" insulin syringe (U-100). 100 units = 1 mL. Pinch skin at abdomen (2" from navel), outer thigh, or love handle. Insert at 45–90°. Rotate sites daily to prevent lipohypertrophy. Alcohol-swab site, air-dry, inject slow, hold 5 sec.
Intravenous (IV)
Clinician-administered only. Reserved for hospital protocols, senolytics research, or emergency use.
IV catheter / infusion pump. Sterile IV push or slow infusion per protocol. Not for home use.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •DSIP for sleep, Pinealon for neuro support
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
Function
Dosing
Recommended Time of Day
Morning, fasted — 10–20 day cycles.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Flank / love handle — Lateral fat pad above the hip. Good rotation site when the abdomen is tender.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
- IV — clinician only — Antecubital vein or central line. Not for home administration.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
10–20 days daily, 2–4 cycles per year.
Timing & Interactions
- ·Active malignancy (theoretical)
- ·DSIP for sleep, Pinealon for neuro support
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Epithalon and sync them to Vial Lab.
Benefits
- ·Reported telomerase activation in vitro
- ·Sleep and circadian improvement
- ·Anti-aging biomarker support (preliminary)
Risks
- ·Limited human RCT data
- ·Long-term safety unproven
- ·Sourcing concerns
Contraindications
- ·Active malignancy (theoretical)
- ·Pregnancy
- ·Any current or prior cancer diagnosis (apoptotic and telomerase pathways are tumor-relevant)
- ·Impaired hepatic or renal clearance (senescent-cell debris burden)
- ·Active wound healing or post-surgical recovery (senescent cells participate in repair)
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Not FDA-approved; research use
Veterinary Use (Pets)
Anti-aging use in geriatric dogs and horses; very limited controlled data.
Functional Groups
Cited Works
Tap any study to open the published work.